Twist Bioscience Announces Fiscal 2024 Fourth Quarter and Full Year Financial Results
18 Novembre 2024 - 1:15PM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap
growth and value equity company in the life sciences segment of the
health care sector, today announced financial results and business
highlights for the fourth quarter and full year fiscal 2024 ended
September 30, 2024.
Visit the Events and Presentations page of the Investor
Relations section under the “Company” tab at
www.twistbioscience.com to view the detailed fiscal fourth
quarter and full year 2024 earnings report and the investor
presentation, or click
https://investors.twistbioscience.com/events-and-presentations.
The company plans to hold a conference call and live audio
webcast for analysts and investors at 8:00 a.m. Eastern Time today
to discuss its financial results and provide an update on the
company’s business. The conference call will be webcast live
through the Investor Relations section under the “Company” tab at
www.twistbioscience.com. Those parties interested in participating
via telephone must register on the Company’s Investor Relations
website or by clicking here. Upon registration, all telephone
participants will receive the dial-in number along with a unique
PIN number that can be used to access the call. To avoid delays, we
encourage participants to dial into the conference call fifteen
minutes ahead of the scheduled start time. The webcast replay will
be available for two weeks.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture, and academic research.
Follow us on LinkedIn | X | YouTube | Instagram
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241118673251/en/
For Investors: Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
For Media: Amanda Houlihan Communications Manager
774-265-5334 ahoulihan@twistbioscience.com
Grafico Azioni Twist Bioscience (NASDAQ:TWST)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Twist Bioscience (NASDAQ:TWST)
Storico
Da Gen 2024 a Gen 2025